ArticleDoklady. Biochemistry and biophysics2025
Influence of Retrodipeptide Analogue of Cholecystokinin Tetrapeptide (GB-115) and Phenazepam on the Behavior of Rhesus Monkeys under Isolation Conditions.
Article in Doklady. Biochemistry and biophysics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe developed domestic retrodipeptide analogue of cholecystokinin tetrapeptide (CCK) (N-(6-phenylhexanoyl)-glycyltryptophan amide, or compound GB-115) with antagonistic properties in relation to CCK1 receptors has anxiolytic activity previously shown in preclinical and clinical studies. The aim of the study was to evaluate the anxiolytic effect of GB-115 as a tablet form with subchronic oral administration in comparison with phenazepam in nonhuman primates. MATERIALS AND
methodsThe study was conducted on four male rhesus monkeys (Macaca mulatta) aged 5.7-6.7 years. After a 30-day adaptation to the conditions of individual caging, experiments were performed first with GB-115 (tablets of 0.001 g) and second with phenazepam (tablets of 0.0005 g). Both drugs were administered one at a time (7 days) and then two tablets each (7 days). Behavior was assessed by observing an object with registration according to the "Yes-No" principle of ethogram elements at the background periods, during the administration of the drugs, and after their withdrawal. The stress response was assessed using cortisol and dehydroepiandrosterone sulfate (DHEA-S) levels as biomarkers determined in the blood serum by enzyme immunoassay.
resultsGB-115 (0.001 g each) and phenazepam (0.001 g each) decreased the stay of the animals in the upper part of the cage compared to the background period, indicating decrease in stress response. GB-115 (0.002 g each) reduced the cortisol/DHEA-S ratio. Phenazepam dose-dependently decreased the level of cortisol in the blood serum without affecting the content of DHEA-S. Under administration of phenazepam (0.001 g each), a decreased cortisol/DHEA-S ratio was also observed.
conclusionsA positive effect of GB-115 upon subchronic administration on the attenuation of the emotional stress response and the restoration of adaptive behavior in rhesus monkeys comparable to the effect of phenazepam was revealed, which confirms the possibility of using blockade of CCK1 receptors as one of the approaches for treating anxiety disorders.
Indexed as
Identifiers
39847298What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.